Table 1:

Mortality reduction for hypothetical cancer screening trials with ten years of follow-up and incidence and stage-specific survival estimated from SEER

Cancer Site	Incidence Hazard Rate (λd)	Early-Stage Mortality Hazard Rate (λ0)	Late-Stage Mortality Hazard Rate (λ1)	Late-Stage Disease Percent (p1)	Stage-Shift Multiplier (ρ)
Ovary	7.38 × 10−6	0.030	0.198	56%	0.636
Lymphoma	0.16 × 10−6	0.027	0.064	51%	0.367
Lung	0.33 × 10−6	0.157	0.570	62%	0.292
Stomach	4.56 × 10−6	0.133	0.586	41%	0.261
Bladder	7.35 × 10−6	0.022	0.489	4%	0.211
Pancreas	6.83 × 10−6	0.319	0.658	61%	0.115
Liver	6.99 × 10−6	0.238	0.692	19%	0.070